$ABUS News

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Arbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of Common Shares At Purchase Price Of Between $5.00 And $5.75 Per Share In Cash

Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate

Arbutus Biopharma: Moderna Validates My IP Bull Case

Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks

Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Biopharma shares are trading higher after the FDA granted the company Fast Track designation for imdusiran for the treatment of chronic hepatitis B

Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B

Arbutus: Q4 Earnings Snapshot